25 Feb 2026
Global policies on generic drugs vary widely-from the U.S.'s high-volume, low-price model to China's aggressive bidding system and South Korea's precision pricing. These approaches save billions but risk quality and supply. Understanding how different countries balance affordability and reliability is key to sustainable healthcare.
25 Dec 2025
Combination NTI drugs offer powerful treatment for complex conditions but face major barriers to generic availability. Despite high demand, no fixed-dose NTI combinations are approved in the U.S. due to unmet bioequivalence standards, leaving patients at risk and providers with few safe options.
